These engineered IL13-zetakine+ T cells exhibit potent MHC-independent, IL13Rα2-specific cytolytic activity against both stem-like and differentiated glioma cells, and induce regression of established glioma xenografts in vivo [11,28]. Here, IL13 is linked to central nervous system cancer.